clinicaltrialsarena on MSN3d
Ocugen doses first subject in Phase I trial of diabetic macular oedema treatment
Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic macular oedema (DMO) treatment.
pharmaphorum5y
Ocugen, Histogenics merge to form eye disease specialist
US biotechs Ocugen and Histogenics have announced plans to merge, creating a specialist in drugs and gene therapies for ocular diseases. Shares in Nasdaq-listed Histogenics almost tripled in the ...
Benzinga.com3mon
Ocugen (NASDAQ:OCGN) Stock Quotes, Forecast and News Summary
Ocugen shares are trading lower by 11% Thursday morning. The company announced the pricing of its public offering. DXC Technology Issues Weak Outlook, Joins Take-Two Interactive And Other Big ...
Buy Rating for X4 Pharmaceuticals Driven by Strategic Partnership and Strong Valuation
X4 Pharmaceuticals (XFOR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Swayampakula ...
Innate Pharma: Promising Pipeline and Strategic Initiatives Support Buy Rating
Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on Innate Pharma (IPHA – Research Report), retaining the price target ...